Sun Pharma Advanced Research Company Ltd (SPRC)

NSE
Currency in INR
156.47
-0.70(-0.45%)
Closed·
SPRC Scorecard
Full Analysis
Short term obligations exceed liquid assets
SPRC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
155.00158.80
52 wk Range
109.30248.00
Key Statistics
Edit
Bid/Ask
156.15 / 156.47
Prev. Close
157.17
Open
156.99
Day's Range
155-158.8
52 wk Range
109.3-248
Volume
232.88K
Average Volume (3m)
1.32M
1-Year Change
-37.49%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SPRC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a poor free cash flow yield
Show more

Sun Pharma Advanced Research Company Ltd Company Profile

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson’s disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer’s disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Employees
409
Market
India

Compare SPRC to Peers and Sector

Metrics to compare
SPRC
Peers
Sector
Relationship
P/E Ratio
−14.9x0.3x−0.5x
PEG Ratio
−1.290.080.00
Price/Book
−23.5x1.0x2.6x
Price / LTM Sales
71.1x0.7x3.0x
Upside (Analyst Target)
-0.0%49.2%
Fair Value Upside
Unlock2.9%7.4%Unlock

Earnings

Latest Release
May 19, 2025
EPS / Forecast
-1.84 / --
Revenue / Forecast
271.90M / --
EPS Revisions
Last 90 days

SPRC Income Statement

People Also Watch

640.05
TRVT
+0.46%
963.45
FNXC
-0.41%
878.65
KECL
-1.04%
1,166.10
INEE
+1.46%

FAQ

What Is the Sun Pharma Adv. Research (SPRC) Stock Price Today?

The Sun Pharma Adv. Research stock price today is 156.47

What Stock Exchange Does Sun Pharma Adv. Research Trade On?

Sun Pharma Adv. Research is listed and trades on the India National Stock Exchange stock exchange.

What Is the Stock Symbol for Sun Pharma Adv. Research?

The stock symbol for Sun Pharma Adv. Research is "SPRC."

What Is the Sun Pharma Adv. Research Market Cap?

As of today, Sun Pharma Adv. Research market cap is 50.78B.

What Is Sun Pharma Adv. Research's Earnings Per Share (TTM)?

The Sun Pharma Adv. Research EPS (TTM) is -10.55.

From a Technical Analysis Perspective, Is SPRC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sun Pharma Adv. Research Stock Split?

Sun Pharma Adv. Research has split 2 times.

How Many Employees Does Sun Pharma Adv. Research Have?

Sun Pharma Adv. Research has 409 employees.

What is the current trading status of Sun Pharma Adv. Research (SPRC)?

As of Jul 09, 2025, Sun Pharma Adv. Research (SPRC) is trading at a price of 156.47, with a previous close of 157.17. The stock has fluctuated within a day range of 155.00 to 158.80, while its 52-week range spans from 109.30 to 248.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.